Citi lowered the firm’s price target on Evolent Health (EVH) to $18 from $21 and keeps a Buy rating on the shares as part of a 2025 outcook for the health technology and distribution group. The firm says that while 2024 was another difficult year for health tech stocks, rather than being driven by deteriorating fundamentals, much of the selloff was due to continued multiple compression, which signals “we have likely reached a valuation floor.” Looking ahead to 2025, Citi is “cautiously optimistic” on the health tech space, saying there seems to be a bit of a post-election risk bid, acquisition activity has accelerated, and expectations have been sufficiently reset. Citi names Health Catalyst (HCAT) its top health tech pick and Cencora (COR) its top distribution pick.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $18 from $27 at JMP Securities
- Evolent Health initiated with a Buy at Needham
- Evolent Health appoints Von Nguyen as Chief Medical Officer
- Evolent Health price target lowered to $15 from $45 at JPMorgan
- Evolent Health price target lowered to $28 from $34 at Oppenheimer
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue